Logo image of XOMAO

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Fundamental Analysis

USA - NASDAQ:XOMAO - US98419J4040

25.49 USD
-0.18 (-0.7%)
Last: 9/30/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, XOMAO scores 4 out of 10 in our fundamental rating. XOMAO was compared to 536 industry peers in the Biotechnology industry. While XOMAO is still in line with the averages on profitability rating, there are concerns on its financial health. XOMAO has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

XOMAO had negative earnings in the past year.
In the past year XOMAO has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMAO reported negative net income in multiple years.
In multiple years XOMAO reported negative operating cash flow during the last 5 years.
XOMAO Yearly Net Income VS EBIT VS OCF VS FCFXOMAO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of XOMAO (-7.93%) is better than 85.26% of its industry peers.
XOMAO's Return On Equity of -19.17% is amongst the best of the industry. XOMAO outperforms 85.45% of its industry peers.
With an excellent Return On Invested Capital value of 3.73%, XOMAO belongs to the best of the industry, outperforming 91.98% of the companies in the same industry.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAO Yearly ROA, ROE, ROICXOMAO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

The Operating Margin of XOMAO (21.23%) is better than 95.15% of its industry peers.
The Profit Margin and Gross Margin are not available for XOMAO so they could not be analyzed.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAO Yearly Profit, Operating, Gross MarginsXOMAO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMAO is destroying value.
XOMAO has more shares outstanding than it did 1 year ago.
XOMAO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XOMAO is higher compared to a year ago.
XOMAO Yearly Shares OutstandingXOMAO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAO Yearly Total Debt VS Total AssetsXOMAO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XOMAO has an Altman-Z score of -5.48. This is a bad value and indicates that XOMAO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.48, XOMAO is doing worse than 62.50% of the companies in the same industry.
XOMAO has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.11, XOMAO is not doing good in the industry: 77.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -5.48
ROIC/WACC0.36
WACC10.35%
XOMAO Yearly LT Debt VS Equity VS FCFXOMAO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.88 indicates that XOMAO has no problem at all paying its short term obligations.
XOMAO has a Current ratio of 4.88. This is comparable to the rest of the industry: XOMAO outperforms 53.17% of its industry peers.
A Quick Ratio of 4.88 indicates that XOMAO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.88, XOMAO is in line with its industry, outperforming 55.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMAO Yearly Current Assets VS Current LiabilitesXOMAO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for XOMAO have decreased strongly by -38.74% in the last year.
Looking at the last year, XOMAO shows a very strong growth in Revenue. The Revenue has grown by 168.71%.
The Revenue has been growing by 9.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

The Earnings Per Share is expected to grow by 37.32% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 35.53% on average over the next years. This is a very strong growth
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAO Yearly Revenue VS EstimatesXOMAO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMAO Yearly EPS VS EstimatesXOMAO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMAO. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 49.66 indicates a quite expensive valuation of XOMAO.
Based on the Price/Forward Earnings ratio, XOMAO is valued cheaper than 88.99% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, XOMAO is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 49.66
XOMAO Price Earnings VS Forward Price EarningsXOMAO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, XOMAO is valued cheaper than 91.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.25
XOMAO Per share dataXOMAO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMAO's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.97%
EPS Next 3Y37.32%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 8.20%, XOMAO is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 170.03, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.44% of the companies listed in the same industry.
XOMAO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.41.
Industry RankSector Rank
Dividend Yield 8.2%

5.2 History

XOMAO has been paying a dividend for over 5 years, so it has already some track record.
XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAO Yearly Dividends per shareXOMAO Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

The earnings of XOMAO are negative and hence is the payout ratio. XOMAO will probably not be able to sustain this dividend level.
DP-30.88%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
XOMAO Yearly Income VS Free CF VS DividendXOMAO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

More info and screens

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (9/30/2025, 8:00:02 PM)

25.49

-0.18 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners68.05%
Inst Owner ChangeN/A
Ins Owners1.4%
Ins Owner ChangeN/A
Market Cap308.17M
Analysts82
Price Target48.12 (88.78%)
Short Float %0.02%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield 8.2%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years3
Ex-Date07-03 2025-07-03 (0.52344)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)-6.48%
PT rev (3m)-29.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)78.18%
EPS NY rev (1m)52.1%
EPS NY rev (3m)198.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)3.63%
Revenue NY rev (3m)10.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 49.66
P/S 6.86
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 6.55
EV/EBITDA 30.25
EPS(TTM)-1.54
EYN/A
EPS(NY)0.51
Fwd EY2.01%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -5.48
F-Score5
WACC10.35%
ROIC/WACC0.36
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.34%
EBIT Next 3Y51.87%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A